ADAMAS PHARMACEUTICALS, INC. (NASDAQ:ADMS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ADAMAS PHARMACEUTICALS, INC. (NASDAQ:ADMS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment of New Chief Financial Officer
On June 26, 2017, the board of directors of Adamas Pharmaceuticals, Inc. (the “Company”) appointed Alfred G. Merriweather as the Company’s Chief Financial Officer, effective June 29, 2017. In such capacity, Mr. Merriweather will also serve as the Company’s principal financial officer and principal accounting officer.
Mr. Merriweather, age 63, has held executive leadership roles at numerous companies in the life sciences industry throughout his career. Before coming to the Company, he was Chief Financial Officer at RainDance Technologies, Inc., a life science tools company, from November 2013 to February 2017, where he was responsible for the finance, information technology, human resources and general legal functions. Prior to RainDance, he served as Chief Financial Officer of Verinata Health, Inc., a prenatal laboratory testing company, from January 2012 to July 2013, where he was responsible for the finance and general legal functions, and as Senior Vice President and Chief Financial Officer of Celera Corporation, a diagnostic products and laboratory testing company, from December 2010 until May 2011, where he was responsible for the finance and information technology functions. Mr. Merriweather has spent over 25 years in senior financial positions at several private and public life science companies, including Monogram Biosciences, Inc. and Laserscope. Mr. Merriweather received a Bachelor’s degree from the University of Cambridge in the United Kingdom.
In connection with Mr. Merriweather’s appointment as the Company’s Chief Financial Officer, the Company entered into an employment offer letter with Mr. Merriweather to which Mr. Merriweather will receive: (a) a base salary of $400,000; (b) a target bonus of 40% of his base salary; (c) a stock option to purchase 112,500 shares of the Company’s Common Stock, and a restricted stock unit award to acquire 18,750 shares of the Company’s Common Stock, in each case vesting over four years; and (d) relocation assistance in an amount of up to $250,000 (which relocation assistance is not subject to any tax gross up).
Retirement of Former Chief Financial Officer
On June 28, 2017, the Company announced the retirement of William Dawson, the Company’s Chief Financial Officer, effective June 29, 2017. In connection with Mr. Dawson’s retirement, on June 27, 2017, the Company entered into a separation agreement with Mr. Dawson to which: (a) Mr. Dawson’s employment will terminate on September 30, 2017; (b) Mr. Dawson ceased to be Chief Financial Officer on June 29, 2017; (c) between June 29, 2017, and September 30, 2017, Mr. Dawson will continue to receive his current base salary; (d) his options will continue to vest and he will continue to be eligible for the Company’s standard benefits, subject to the terms of such plans and programs; (e) subject to the conditions set forth in the separation and consulting agreement, the Company shall retain Mr. Dawson as a consultant from October 1, 2017, through March 31, 2018, and if so retained Mr. Dawson will receive consulting fees in the amount of $15,000 per month; (f) the vesting of Mr. Dawson’s stock options shall cease on September 30, 2017; and (g) the post-termination option exercise period of such option shall continue until June 30, 2019.
Mr. Dawson’s separation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

About ADAMAS PHARMACEUTICALS, INC. (NASDAQ:ADMS)

Adamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues. It has developed a portfolio of chrono-synchronous therapies to address chronic neurologic disorders. Its first product candidate is ADS-5102, a chrono-synchronous amantadine therapy, for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease (PD). It has completed Phase II proof-of-concept study of ADS-5102 in these patients. Its Phase III clinical program included three placebo-controlled trials: EASED, EASE LID and EASE LID 3. Its second product candidate is ADS-4101, an extended-release version of single-agent compound for the treatment of epilepsy (partial onset seizures).

An ad to help with our costs